![John P. Hennessey](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John P. Hennessey
Hoofd Techniek/Wetenschap/O&O bij NovaDigm Therapeutics, Inc.
Actieve functies van John P. Hennessey
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NovaDigm Therapeutics, Inc.
![]() NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Hoofd Techniek/Wetenschap/O&O | - | - |
Loopbaan van John P. Hennessey
Eerdere bekende functies van John P. Hennessey
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Statistieken
Internationaal
Verenigde Staten | 3 |
Operationeel
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
NovaDigm Therapeutics, Inc.
![]() NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Health Technology |
- Beurs
- Insiders
- John P. Hennessey
- Ervaring